#6
Intellia Therapeutics
The $2B valuation pioneer of in vivo CRISPR gene editing, delivering gene corrections directly inside the human body. Its NTLA-2001 program for transthyretin amyloidosis showed landmark results with a single infusion, achieving 90% reduction in serum TTR protein levels.
Photos (1)
Comments on "Intellia Therapeutics"
Have a take on this ranking?
Comments are how the argument actually happens here. Posting one needs a free account — it takes about a minute.
No comments yet.
The first comment sets the terms of the argument.